These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 37997380

  • 1. Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.
    Wu L, Carlino MS, Brown DA, Long GV, Clifton-Bligh R, Mellor R, Moore K, Sasson SC, Menzies AM, Tsang V, Gunton JE.
    J Clin Endocrinol Metab; 2024 Apr 19; 109(5):1301-1307. PubMed ID: 37997380
    [Abstract] [Full Text] [Related]

  • 2. Risk Factors and Characteristics of Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes.
    Wu L, Tsang V, Menzies AM, Sasson SC, Carlino MS, Brown DA, Clifton-Bligh R, Gunton JE.
    Diabetes Care; 2023 Jun 01; 46(6):1292-1299. PubMed ID: 37220262
    [Abstract] [Full Text] [Related]

  • 3. Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.
    Tsang VHM, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, Long GV, Menzies AM.
    J Clin Endocrinol Metab; 2019 Nov 01; 104(11):5499-5506. PubMed ID: 31265074
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
    Grimmelmann I, Momma M, Zimmer L, Hassel JC, Heinzerling L, Pföhler C, Loquai C, Ruini C, Utikal J, Thoms KM, Kähler KC, Eigentler T, Herbst RA, Meier F, Debus D, Berking C, Kochanek C, Ugurel S, Gutzmer R, German Dermatooncology Group (DeCOG).
    Eur J Cancer; 2021 May 01; 149():1-10. PubMed ID: 33812141
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis.
    Zhang AL, Wang F, Chang LS, McDonnell ME, Min L.
    Front Endocrinol (Lausanne); 2021 May 01; 12():620522. PubMed ID: 33927691
    [Abstract] [Full Text] [Related]

  • 9. Clinical and HLA genotype analysis of immune checkpoint inhibitor-associated diabetes mellitus: a single-center case series from China.
    Liu YC, Liu H, Zhao SL, Chen K, Jin P.
    Front Immunol; 2023 May 01; 14():1164120. PubMed ID: 37359544
    [Abstract] [Full Text] [Related]

  • 10. Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside.
    Wu L, Tsang VHM, Sasson SC, Menzies AM, Carlino MS, Brown DA, Clifton-Bligh R, Gunton JE.
    Front Endocrinol (Lausanne); 2021 May 01; 12():764138. PubMed ID: 34803927
    [Abstract] [Full Text] [Related]

  • 11. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
    Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y.
    J Immunother Cancer; 2019 Feb 06; 7(1):31. PubMed ID: 30728076
    [Abstract] [Full Text] [Related]

  • 12. The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy.
    Basak EA, de Joode K, Uyl TJJ, van der Wal R, Schreurs MWJ, van den Berg SAA, Oomen-de Hoop E, van der Leest CH, Chaker L, Feelders RA, van der Veldt AAM, Joosse A, Koolen SLW, Aerts JGJV, Mathijssen RHJ, Bins S.
    Biomed Pharmacother; 2022 Dec 06; 156():113839. PubMed ID: 36228374
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism.
    Patel S, Chin V, Greenfield JR.
    Endocrinol Diabetes Metab Case Rep; 2019 Dec 12; 2019():. PubMed ID: 31829972
    [Abstract] [Full Text] [Related]

  • 16. Letter to the Editor from Hao and Xue: "Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy".
    Hao L, Xue J.
    J Clin Endocrinol Metab; 2024 Aug 16. PubMed ID: 39148462
    [No Abstract] [Full Text] [Related]

  • 17. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
    de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, Gorus FK, Roep BO, Aspeslagh S, Neyns B, Velkeniers B, Kharagjitsingh AV.
    Eur J Endocrinol; 2019 Sep 16; 181(3):363-374. PubMed ID: 31330498
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.